Faeth Therapeutics, Inc. (NASDAQ: FTH) is a Healthcare company (Biotechnology) with a market capitalization of $275M. The Maz Rating grades it against the other companies in its sector.
About three months ago (July 2, 2026), Faeth Therapeutics, Inc. had a Maz Rating of 4.18 out of 5 (A, Strong Buy), ranked against the other companies in its sector. Its strongest factor then was Valuation (4.57), among the most attractively valued in its sector; its weakest was Growth (1.72), below most of its sector. The other factors: Momentum 4.22 (above most of its sector); Financial Health 3.93 (above most of its sector); Profitability 2.08 (below most of its sector). The current rating is for members: log in to see it.
At $10.65, Faeth Therapeutics, Inc. trades at 1.7x book value. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -153.5%, return on invested capital of -128.6% and a free cash flow yield of -15.5%. On the balance sheet: a debt-to-equity ratio of 0.00 and a current ratio of 16.12. Over the past 52 weeks the share price ranged from $7.45 to $42.14, with a beta of -0.30.
Faeth Therapeutics, Inc. does not currently pay a dividend.
6 Wall Street analyst ratings cover the stock: 6 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.